The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJHemOnc presents the Waldenström’s Macroglobulinemia Channel
Welcome to the Waldenström’s Macroglobulinemia Channel, bringing you the latest data from world-renowned experts on Waldenström’s macroglobulinemia through exclusive interviews, podcasts, roundtable discussions, and more.
Explore the latest advances, such as rituximab and proteasome inhibitor-based therapies that have demonstrated efficacy in symptom management, and targeted therapies that are increasingly playing a role in tailoring treatment options, directly from leading experts on the Waldenström’s Macroglobulinemia Channel.
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
Diamond Supporter
Gold Supporter
Silver Supporter
Bronze Supporter
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.
